Your browser doesn't support javascript.
loading
Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.
Ryan, Donna H; Deanfield, John E; Jacob, Stephan.
Afiliação
  • Ryan DH; Pennington Biomedical Research Center, Baton Rouge, LA, USA.
  • Deanfield JE; Institute of Cardiovascular Sciences, University College London, London, UK.
  • Jacob S; Department of Internal Medicine, Division of Endocrinology/Diabetology, Cardiometabolic Institute, Villingen-Schwenningen, Germany.
Cardiovasc Endocrinol Metab ; 12(1): e0279, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36777095
ABSTRACT
Obesity is a major risk factor for cardiovascular disease, yet management remains poor. Cardiologists and healthcare professionals treating people with high cardiovascular risk are in a position to address overweight and obesity to improve cardiovascular health. There are several treatment options for obesity, which are associated with numerous health benefits. Modest weight reductions of 5-10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can support weight reduction when lifestyle modifications alone are insufficient. The weight loss induced by these treatments can improve cardiovascular risk, and some therapies - such as glucagon-like-peptide-1 analogues - may promote these benefits independently of weight loss. Bariatric surgery can induce greater weight losses than other treatment modalities and is associated with numerous health benefits, but newer medications such as semaglutide and those in development, such as tirzepatide, produce robust weight loss efficacy that is approaching that of bariatric surgery. Healthcare professionals must approach this disease with compassion and collaborate with patients to develop sustainable plans that improve health and maintain weight loss over the long term.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cardiovasc Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cardiovasc Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos